Working… Menu

UCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03158883
Recruitment Status : Recruiting
First Posted : May 18, 2017
Last Update Posted : July 8, 2020
EMD Serono
Information provided by (Responsible Party):
Megan Daly, MD, University of California, Davis

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : January 1, 2022
Estimated Study Completion Date : June 1, 2022